Press Releases

August 5, 2022

Regulatory

SynAct Pharma publishes Q2 2022 interim report

July 12, 2022

Regulatory

Trading in SynAct Pharma’s shares on Nasdaq Stockholm commences today

July 8, 2022

Regulatory

SynAct Pharma AB publishes prospectus for list change to Nasdaq Stockholm

June 29, 2022

Regulatory

SynAct Pharma recieves pre-IND response from the US FDA

June 28, 2022

Regulatory

SynAct Pharma AB has been approved for listing on Nasdaq Stockholm

May 30, 2022

Regulatory

SynAct Pharma publishes Q1 2022 interim report

May 20, 2022

Regulatory

Bulletin from the annual general meeting in SynAct Pharma AB on May 20, 2022

May 12, 2022

Regulatory

Last day of trading in paid subscribed shares (Sw. betalda tecknade aktier) in SynAct Pharma AB

April 29, 2022

Regulatory

SynAct Pharma AB publishes Annual Report 2021

April 25, 2022

Regulatory

SynAct announces outcome of rights issue

April 20, 2022

Regulatory

Notice of annual general meeting in SynAct Pharma AB

March 28, 2022

Regulatory

Bulletin from the extraordinary general meeting on March 28, 2022, in SynAct Pharma AB

March 28, 2022

Regulatory

SynAct resolves on a fully guaranteed rights issue of approximately SEK 150 million

March 9, 2022

Regulatory

Notice of extraordinary general meeting in SynAct Pharma AB

March 9, 2022

Regulatory

The Nomination Committee proposes Kerstin Hasselgren as a new board member of SynAct Pharma AB

February 11, 2022

Regulatory

Annual Results 2021